Fluvastatin Improves Insulin Resistance in Nondiabetic Dyslpidemic Patients
Endocrine, cilt.22, sa.2, ss.151-153, 2003 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 22 Sayı: 2
- Basım Tarihi: 2003
- Doi Numarası: 10.1385/endo:22:2:151
- Dergi Adı: Endocrine
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.151-153
- Anahtar Kelimeler: insulin resistance, fluvastatin, dyslipidemia
- Sağlık Bilimleri Üniversitesi Adresli: Hayır
Özet
Statins have multiple actions, independent of their classical effects on lipoproteins. The data about the effects of statins on insulin resistance is controversial. This study was designed to search the statin effects on nondiabetic dyslipidemic patients. Thirty-five (17 male, 18 female) consecutive dyslipidemic patients 54.25 ± 8.81 yr were enrolled in the study. After a standard follow-up period of lifestyle modification, the patients were given fluvastatin 40 mg/d for 8 wk. Serum analyses were done both before and after treatment. Insulin resistance was assessed by homeostasis assessment model (HOMA). Fasting plasma triglyceride, total and LDL cholesterol, fasting insulin, and HOMA index were significantly reduced and HDL cholesterol was improved after fluvastatin treatment. HOMA-IR was not correlated with triglycerides, LDL, HDL, or total cholesterol levels. The same situation was present for both fasting plasma insulin and fasting plasma glucose levels. Also age was not associated with HOMA-IR and fasting plasma insulin levels. As a conclusion, the present study indicates that fluvastatin treatment improves insulin resistance in dyslipidemic patients who do not have diabetes or impaired fasting glucose. Also, the effect of fluvastatin on insulin resistance is not associated with the lowering of triglycerides. The latter finding indicates that the effect of statins on insulin sensitivity may not be related with the lowering of triglycerides in dyslipidemic patients. Indications:35 patients with insulin resistance and dyslipidemia. Patients:35 outpatients (17 male and 18 female, mean age 54.25 ± 8.81 years). TypeofStudy:A study investigating the effect of Lescol on insulin resistance in a selected group of patients who have only dyslipidemia. DosageDuration:40 mg daily for 8 weeks. Results:No difference of body mass index, mean arterial blood pressure, and fasting plasma glucose was present in the end of treatment. Fasting plasma triglycerides, total cholesterol, LDL cholesterol, fasting insulin, and HOMA index were significantly reduced after Lescol treatment. Fasting plasma HDL cholesterol was improved significantly. The HOMA-IR was not correlated with triglycerides, LDL, HDL, and total cholesterol levels. The same situation was present for both fasting plasma insulin and fasting plasma glucose levels. Also, age was not associated with HOMA-IR and fasting plasma insulin levels. AdverseEffects:No adverse events were mentioned. AuthorsConclusions:In conclusion, the present study shows that fluvastatin treatment improves insulin resistance in dyslipidemic patients who perform therapeutic lifestyle modifications and who have no diabetes or impaired fasting glucose. Also, the effect of fluvastatin on insulin resistance is not related with the lowering of triglycerides. FreeText:Fasting blood samples were collected from patients between 08:00 and 08:30 AM after a 12 hour (h) fasting. The tubes were promptly centrifuged; plasma was separated and stored at -70° C for measurement of glucose, total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL) cholesterol. All plasma samples were run in a single assay. Glucose, total cholesterol, TG, and HDL cholesterol were measured by the enzymatic colorimetric method. Insulin resistance score (HOMA-IR). Low HOMA-IR values indicate high insulin sensitivity, whereas high HOMA-IR values indicate low insulin sensitivity (insulin resistance). Other tests: body mass index, mean arterial pressure.